, Volume 16, Issue 12, pp 3455-3462,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 28 Jul 2009

S-100B Concentrations Predict Disease-Free Survival in Stage III Melanoma Patients

Abstract

Background

Elevation of the tumor marker S-100B in melanoma patients is a highly specific indicator of recurrence.

Materials and methods

The role of S-100B in disease-free survival (DFS) was evaluated in stage III melanoma patients (staged with fluorodeoxyglucose positron emission tomography [FDG-PET] and computed tomography [CT]) with palpable lymph node metastases who underwent therapeutic lymph node dissection. S-100B and LDH were measured on the day before surgery (d = −1) and on days 1, 2, and 7 postoperatively. Multivariate logistic regression was used to study factors associated with preoperative elevation of S-100B. Univariate (log-rank test) and multivariate (Cox regression) survival analyses were performed to identify factors associated with DFS.

Results

Between 2004 and 2008, 56 patients (median age 57, range 24–93) years, 27 males (48%) and 29 females (52%) entered the study. Preoperative S-100B elevation was found in 27 patients (48%) and elevated LDH in 20 patients (36%). No association was found between these two markers at any time. Multivariate analysis showed that elevated S-100B preoperatively (hazard ratio [HR] 2.7, P = .03) was associated with DFS. S-100B elevation was associated with increased tumor size (odds ratio [OR] 3.40; P = .03).

Conclusion

Elevated S-100B preoperatively in patients with optimally staged clinical stage III melanoma is associated with decreased disease-free survival. S100-B could be used as a prognostic marker in the stratification of new adjuvant trials to select stage III melanoma patients for adjuvant systematic treatment.

Presented at the 14th Congress of the European Society of Surgical Oncology, The Hague, The Netherlands, September 10–12, 2008.
An erratum to this article can be found at http://dx.doi.org/10.1245/s10434-009-0828-3